Ligand Pharmaceuticals Acquires Xoma for Approximately $740 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 27 2026
0mins
Source: WSJ
Investment in Drug Development: Ligand and Xoma are recognized as royalty aggregators that invest in drug development.
Revenue from Successful Drugs: They collect royalties from their sales if the drugs they invest in succeed.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
